We are live on
!
Find out more
Alnylam Pharmaceuticals
ALNY
ALNY
304 hedge funds and large institutions have $7.94B invested in Alnylam Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 115 increasing their positions, 94 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
32% more call options, than puts
Call options by funds: $139M | Put options by funds: $105M
22% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 94
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1% less ownership
Funds ownership: 91.08% → 90.08% (-1%)
2% less funds holding
Funds holding: 309 → 304 (-5)
11% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 38
12% less capital invested
Capital invested by funds: $9B → $7.94B (-$1.06B)
Holders
304
Holders Change
-5
Holders Change %
-1.62%
% of All Funds
6.95%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.21%
New
34
Increased
115
Reduced
94
Closed
38
Calls
$139M
Puts
$105M
Net Calls
+$33.3M
Net Calls Change
-$16.5M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$125M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$83.6M |
| 3 |
JP Morgan Chase
New York
|
+$35.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$31.7M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.9M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$125M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$102M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$69M |
| 4 |
PA
Perceptive Advisors
New York
|
-$65.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$47.4M |
